Methods and systems for inhibiting foreign-body responses in diabetic patients
Sarnath Chattaraj, Simi Valley, CA (US); Kiem H. Dang, Thousand Oaks, CA (US); Hsi Chung Fusselman, Simi Valley, CA (US); Poonam S. Gulati, La Canada, CA (US); Lance P. Hoffman, West Hollywood, CA (US); and Guangping Zhang, Calabasas, CA (US)
Assigned to Medtronic MiniMed, Inc., Northridge, CA (US)
Filed by Medtronic MiniMed, Inc., Northridge, CA (US)
Filed on Nov. 22, 2019, as Appl. No. 16/693,050.
Application 16/693,050 is a continuation of application No. 14/512,788, filed on Oct. 13, 2014, granted, now 10,517,892.
Claims priority of provisional application 62/032,101, filed on Aug. 1, 2014.
Claims priority of provisional application 61/935,010, filed on Feb. 3, 2014.
Claims priority of provisional application 61/894,088, filed on Oct. 22, 2013.
1. A system for delivering insulin to a diabetic patient at a single site of infusion over a period of time, the system comprising: a medication reservoir comprising an insulin solution; a cannula adapted for subcutaneous insertion into a tissue of a diabetic patient at the single site of infusion; a fluid conduit in operable contact with the medication reservoir and the cannula and adapted to deliver insulin from the medication reservoir to the single site of infusion; a site loss mitigating agent comprising rapamycin that inhibits inflammation at the single site of infusion; and wherein the system delivers an amount of rapamycin sufficient to inhibit inflammation at the single site of infusion for a period of time of at least 4 days.
